Samsung Bioepis Executives Weigh US Biosimilar Progress
For The US Biosimilars Market, ‘Pace Of Progress Has To Improve To Ensure Future Viability’
In an exclusive Q&A interview with Generics Bulletin, Samsung Bioepis executives Tom Newcomer and Gillian Woollett discuss the progress made by US biosimilars so far, the developments that are expected in the months and years to come, as well as the action that is needed to ensure a viable biosimilars market going forward.
You may also be interested in...
The launch of competition to Humira was the main event for US biosimilars this year – but a number of other key developments also took place in 2023, including settlements on Stelara that set up a series of launches in 2025, as well as first approvals for ustekinumab, natalizumab and tocilizumab biosimilars.
Amid continuing stakeholder confusion over the meaning and significance of the US FDA’s interchangeability designation for biosimilars, the agency has now recommended omitting altogether details of interchangeability from biosimilar labels.
Samsung Bioepis has celebrated becoming the first developer to obtain approvals for both Lucentis and Eylea biosimilars, after its SB15 aflibercept candidate was approved in Korea.